Renal and cardiovascular characterization of COX-2 knockdown mice

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 296, Issue 6, 2009, Pages

  Seta, Francesca ^a   Chung, Andrew D ^a   Turner, Patricia V ^b   Mewburn, Jeffrey D ^c   Yu, Ying ^a,d   Funk, Colin D ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Induced mutant mice; Kidney; Macrophage; Prostacyclin; Prostaglandin synthase; Thrombosis

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FERRIC CHLORIDE; FLUORESCEIN ISOTHIOCYANATE; INULIN; LIPOPOLYSACCHARIDE; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTANOID; THROMBOXANE; UREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOLE; ARTERY THROMBOSIS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREMASTER MUSCLE; ENDOTHELIUM CELL; EX VIVO STUDY; FEMALE; INULIN CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KNOCKOUT MOUSE; MACROPHAGE; MALE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; THROMBOCYTE AGGREGATION; THROMBOGENESIS; UREA NITROGEN BLOOD LEVEL; URINALYSIS; WILD TYPE;

ANIMALS; BLOOD PRESSURE; BLOOD UREA NITROGEN; CARDIOVASCULAR SYSTEM; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EPOPROSTENOL; FERRIC COMPOUNDS; GLOMERULAR FILTRATION RATE; HEART RATE; KIDNEY; MACROPHAGES, PERITONEAL; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICROSCOPY, VIDEO; THROMBOSIS; THROMBOXANE B2; TIME FACTORS;

EID: 67049161991     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.90985.2008     Document Type: Article

References (38)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528, 2000.
2. Brash AR, Jackson EK, Saggese CA, Lawson JA, Oates JA, FitzGerald GA. Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther 226: 78-87, 1983.
3. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005. (Pubitemid 40365350)
4. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289: 735-741, 1999. (Pubitemid 29191226)
5. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539-541, 2002. (Pubitemid 34408674)
6. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, FitzGerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116: 1391-1399, 2006.
7. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, Trzaskos JM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378: 406-409, 1995.
8. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 8: 1175-1181, 2002. (Pubitemid 35175975)
9. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase- 2. N Engl J Med 345: 433-442, 2001.
10. Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim HS, Rockman HA, FitzGerald GA, Koller BH, Coffman TM. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2:201-207, 2005.
11. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875, 2001. (Pubitemid 33101574)
12. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 50: 470-479, 2007. (Pubitemid 350146448)
13. Ghosh M, Wang H, Ai Y, Romeo E, Luyendyk JP, Peters JM, Mackman N, Dey SK, Hla T. COX-2 suppresses tissue factor expression via endocannabinoid- directed PPARΔ activation. J Exp Med 204: 2053-2061, 2007. (Pubitemid 47360868)
14. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15, 2006. (Pubitemid 43121782)
15. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94: 2504-2510, 1994. (Pubitemid 24379628)
16. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104: 820-825, 2001. (Pubitemid 32762682)
17. Hong TT, Huang J, Barrett TD, Lucchesi BR. Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am J Physiol Heart Circ Physiol 294: H145-H155, 2008.
18. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277, 1999. (Pubitemid 29036089)
19. McAdam BF, Mardini IA, Habib A, Burke A, Lawson JA, Kapoor S, FitzGerald GA. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 105: 1473-1482, 2000. (Pubitemid 30322413)
20. Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR, Warner TD. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase- 1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J 20: 2468-2475, 2006. (Pubitemid 44953819)
21. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482, 1995.
22. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388: 678-682, 1997. (Pubitemid 27366439)
23. Norwood VF, Morham SG, Smithies O. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int 58: 2291-2300, 2000.
24. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383, 2005. (Pubitemid 41713749)
25. Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB, Breyer MD. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 286: F590-F596, 2004. (Pubitemid 38233654)
26. Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, Pape R, Fischer JW, Schror K, Weber AA. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 96: e1-e6, 2005.
27. Rosenkranz B, Kitajima W, Frolich JC. Relevance of urinary 6-ketoprostaglandin F1α determination. Kidney Int 19: 755-759, 1981.
28. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66: 76-84, 1999. (Pubitemid 29350448)
29. Rudic RD, Brinster D, Cheng Y, Fries S, Song WL, Austin S, Coffman TM, FitzGerald GA. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 96: 1240-1247, 2005. (Pubitemid 40962101)
30. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
31. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117: 2104-2113, 2008.
32. Stichtenoth DO, Marhauer V, Tsikas D, Gutzki FM, Frolich JC. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int 68: 2197-2207, 2005. (Pubitemid 43117794)
33. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232-235, 1971.
34. Wassarman KM, Lewandoski M, Campbell K, Joyner AL, Rubenstein JL, Martinez S, Martin GR. Specification of the anterior hindbrain and establishment of a normal mid/hindbrain organizer is dependent on Gbx2 gene function. Development 124: 2923-2934, 1997. (Pubitemid 27370908)
35. Yang T, Huang YG, Ye W, Hansen P, Schnermann JB, Briggs JP. Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. Am J Physiol Renal Physiol 288: F1125-F1132, 2005. (Pubitemid 40677082)
36. Yu Y, Cheng Y, Fan J, Chen XS, Klein-Szanto A, FitzGerald GA, Funk CD. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest 115: 986-995, 2005. (Pubitemid 40489403)
37. Yu Y, Fan J, Chen XS, Wang D, Klein-Szanto AJ, Campbell RL, FitzGerald GA, Funk CD. Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat Med 12: 699-704, 2006. (Pubitemid 43865241)
38. Yu Y, Fan J, Hui Y, Rouzer CA, Marnett LJ, Klein-Szanto AJ, FitzGerald GA, Funk CD. Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. J Biol Chem 282: 1498-1506, 2007. (Pubitemid 47076579)